All In Biotech

NDA 020478 · Abbvie

Ultane

Sevoflurane · Inhalation · General Anesthetic

Novel

Last checked: Nov 19, 2026Latest source record: Feb 3, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1995

Jun 7, 1995

Approved uses

2

Original approval plus efficacy supplements

Registered trials

832

71 Phase 3, 53 recruiting

FAERS reports

8,423

7,983 serious, 569 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Feb 12, 2025.

INDICATIONS AND USAGE ULTANE is indicated for induction and maintenance of general anesthesia in adult and pediatric patients for inpatient and outpatient surgery. ULTANE should be administered only by persons trained in the administration of general anesthesia. Facilities for maintenance of a patent airway, artificial ventilation, oxygen enrichment, and circulatory resuscitation must be immediately available. Since level of anesthesia may be altered rapidly, only vaporizers producing predictable concentrations of sevoflurane should be used.

Therapeutic areas: Pain and anesthesia

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Mar 30, 2001 Supplement 6 · Efficacy LabelReviewLetter
  • Jun 7, 1995 Original approval · Type 1 - New Molecular Entity Review
1 products under this application
  • ULTANE · SEVOFLURANE 100% · LIQUID, INHALATION · Prescription · TE AN

Clinical trials

Interventional ClinicalTrials.gov studies with "Sevoflurane" as an intervention, any sponsor and status, largest first.

All 832 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • hypotension612
  • anaesthetic complication neurological522
  • drug interaction499
  • cardiac arrest430
  • bradycardia380
  • hyperthermia malignant299
  • drug ineffective298
  • tachycardia279
  • anaphylactic shock263
  • serotonin syndrome252
  • anaphylactic reaction237
  • foetal exposure during pregnancy236

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004183
2005143
2006145
2007190
2008251
2009281
2010245
2011371
2012432
2013417
2014304
2015237
2016382
2017328
2018445
2019348
2020401
2021497
2022460
2023524
2024449
2025684
2026704

Recalls

1 FDA enforcement reports for this application.

  • Jan 22, 2018 · Class III · Terminated

    Defective container: presence of a hole in the liners of the caps covering the product bottle, introducing possibility of leakage.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 3,042 on PubMed

Sponsor: AbbVie

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.